

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sarcoma | D012509 | — | — | 1 | 1 | — | — | 1 | 3 |
| Lymphoma | D008223 | — | C85.9 | — | 3 | — | — | — | 3 |
| Osteosarcoma | D012516 | — | — | 1 | 3 | — | — | — | 3 |
| Neoplasms | D009369 | — | C80 | 2 | 1 | — | — | — | 2 |
| Recurrence | D012008 | — | — | — | 1 | — | — | — | 1 |
| Hodgkin disease | D006689 | — | C81 | — | 1 | — | — | — | 1 |
| Sclerosis | D012598 | — | — | — | 1 | — | — | — | 1 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | 1 | 1 | — | — | — | 1 |
| Central nervous system neoplasms | D016543 | — | — | — | 1 | — | — | — | 1 |
| Ewing sarcoma | D012512 | EFO_0000173 | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuroblastoma | D009447 | EFO_0000621 | — | 1 | — | — | — | — | 1 |
| Bone neoplasms | D001859 | EFO_0003820 | D16 | 1 | — | — | — | — | 1 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
| Drug common name | Palifosfamide |
| INN | palifosfamide |
| Description | Isophosphamide mustard is a phosphorodiamide. |
| Classification | Small molecule |
| Drug class | phosphoro-derivatives; isophosphoramide mustard derivatives |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | O=P(O)(NCCCl)NCCCl |
| PDB | — |
| CAS-ID | 31645-39-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL889 |
| ChEBI ID | 80566 |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 6A4U6NN813 (ChemIDplus, GSRS) |

